Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

End-of-day quote. End-of-day quote  - 08/17
35.5 USD   +0.51%
05:14p PFIZER : Gas price ticks up to $1.96 in Tulsa
03:32p PFIZER : dumps split
09:02a PFIZER : Wall Street ends lower
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Pfizer Inc. : Pfizer Names Olivier Brandicourt as President and General Manager, Emerging Markets and Established Products Business Units

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/23/2012 | 01:35pm CEST

John Young Named President and General Manager, Primary Care Business Unit

Pfizer Inc. (NYSE: PFE) named Olivier Brandicourt as President and General Manager of the Emerging Markets and Established Products Business Units, effective June 1, 2012. He will succeed David Simmons, who is leaving Pfizer to become the Chairman and CEO of Pharmaceutical Product Development Inc. (PPD), a privately held global contract research organization.

"Olivier is ideally suited to take on this new role," said Ian Read, Pfizer Chairman and CEO. "He has more than 20 years of global experience in the pharmaceutical industry. Olivier is both a physician and proven business leader who understands the many challenges of today's changing industry and healthcare landscape."

Dr. Brandicourt has held senior positions at Pfizer across a range of disciplines, including medical and marketing, as well as country and regional management roles in Latin America, Europe, Canada, the United Kingdom and the United States. Most recently, he served as President and General Manager of the Primary Care Business Unit and is a member of the Pfizer Executive Leadership Team. He is an Honorary Fellow of the Royal College of Physicians in London and a trustee of the Children's Aid Society of New York.

John Young, currently Regional President of Europe and Canada for the Primary Care business, is appointed President and General Manager of the Primary Care Business Unit and will join the Company's Executive Leadership Team, effective June 1, 2012. Over his 25-year career with Pfizer, Mr. Young has held a number of commercial positions with the company, including country and regional management roles in Australia/New Zealand and the United Kingdom.

"John has a deep understanding of the primary care landscape and will be a strong leader for this significant part of our business. We are indeed fortunate to have such a deep bench of talented leaders who can quickly assume new roles and maintain our momentum," Read added.

"We thank David for his contributions throughout his 15-year career at Pfizer. Under his leadership, the Established Products Business Unit was created, expanding Pfizer's market reach while also helping to ensure patients have the access to high-quality, affordable medicines they need."

Pfizer Inc: Working Together for a Healthier World™

At Pfizer (NYSE: PFE), we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

Pfizer Inc.
Media Contact:
Joan Campion, 212-733-2798
or
Investors Contact:
Chuck Triano, 212-733-3901


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER INC
05:14p PFIZER : Gas price ticks up to $1.96 in Tulsa
03:32p PFIZER : dumps split
11:59a PFIZER CONCLUDES Rs110-CRORE DEAL WITH PIRAMAL
11:14a PFIZER : drops bid to split into two
09:02a PFIZER : Wall Street ends lower
09:02a PFIZER : Sensex, Nifty to open on flat note
08:49aDJPFIZER : Scraps Plan to Break Up Company -- WSJ
07:11a DEUTSCHE BANK : Pfizer decision hurts shares
09/26 PFIZER : Business Highlights
09/26 Deutsche Bank, Pfizer slide; Transocean and Chemtura climb
More news
Sector news : Pharmaceuticals - NEC
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update
2015 Antibiotics Stocks To Benefit From 21st Century Cures Act
2015 ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case
2015 DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb
2015 Pfizer's GL-2045 an Orphan Drug for CIDP
Advertisement
Financials ($)
Sales 2016 52 840 M
EBIT 2016 19 432 M
Net income 2016 12 132 M
Debt 2016 23 068 M
Yield 2016 3,54%
P/E ratio 2016 18,45
P/E ratio 2017 15,31
EV / Sales 2016 4,30x
EV / Sales 2017 4,03x
Capitalization 204 049 M
More Financials
Chart PFIZER INC
Duration : Period :
Pfizer Inc Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 39,5 $
Spread / Average Target 17%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Mikael Dolsten President-Worldwide Research & Development
Ole Isacson Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC13.96%204 049
JOHNSON & JOHNSON14.66%322 232
ROCHE HOLDING LTD.-11.18%215 081
NOVARTIS AG-8.70%211 231
PFIZER INC.4.21%204 049
MERCK & CO., INC.17.66%171 858
More Results